Sin B, Misirligil Z, Aybay C, Gürbüz L, Imir T
Ankara University, Faculty of Medicine, Department of Allergic Diseases, Turkey.
J Investig Allergol Clin Immunol. 1996 Nov-Dec;6(6):341-7.
Allergen specific immunotherapy (IT) has been widely used for many years as a specific treatment of allergic diseases. A variety of changes in immunological parameters have been described but it still remains uncertain as to which of them is responsible for the improvement of symptoms. The aim of our study was to evaluate the effect of IT on natural killer (NK) cell activity, IL-4, IFN-gamma, IgE levels and skin test reactivity in addition to clinical efficacy. Thirty-one patients with allergic rhinitis and asthma were selected according to positive history, skin prick tests to Dermatophagoides pteronyssinus (Der p) or grass pollens, presence of specific IgE antibodies in sera and clinical findings, and were submitted to one year of placebo-controlled IT. Total IgE, specific IgE, IL-4 and IFN-gamma levels were measured by using ELISA method. Standard chromium 51 release assay was used to measure NK cell cytotoxic activity against the human leukemic cell line, K562 target cells. Mean symptom and medication scores, skin test reactivity and histamine sensitivity were significantly decreased in the patients given IT at the end of the first year when compared with the placebo group. However, there was neither a significant reduction in total and specific IgE levels nor a significant increase in IFN-gamma levels at the first year of IT. IL-4 levels were only measured at the beginning of the study because of the very low levels. A decrease in NK cell activity was found in patients treated with grass pollen extracts after 12 months when compared with Der p and placebo group. No signs of major local or systemic side effects due to IT were seen in patients during the study. Although significant clinical efficacy of specific IT with standardized extracts has been demonstrated in allergic rhinitis and asthmatic patients at the end of the first year of IT, no significant changes in immunological parameters were observed. However we conclude that a decrease in NK cell cytotoxic activity during IT has to be taken into account in the follow-up of patients.
变应原特异性免疫疗法(IT)作为过敏性疾病的一种特异性治疗方法已被广泛应用多年。免疫参数出现了多种变化,但仍不确定其中哪些变化导致了症状的改善。我们研究的目的是除了评估IT的临床疗效外,还评估其对自然杀伤(NK)细胞活性、白细胞介素-4(IL-4)、干扰素-γ(IFN-γ)、免疫球蛋白E(IgE)水平及皮肤试验反应性的影响。根据阳性病史、对屋尘螨(Der p)或草花粉的皮肤点刺试验、血清中特异性IgE抗体的存在情况及临床症状,选择了31例过敏性鼻炎和哮喘患者,并对其进行了为期一年的安慰剂对照IT治疗。采用酶联免疫吸附测定(ELISA)法检测总IgE、特异性IgE、IL-4和IFN-γ水平。采用标准铬51释放试验检测NK细胞对人白血病细胞系K562靶细胞的细胞毒性活性。与安慰剂组相比,接受IT治疗的患者在第一年结束时平均症状和用药评分、皮肤试验反应性及组胺敏感性显著降低。然而,在IT治疗的第一年,总IgE和特异性IgE水平均未显著降低,IFN-γ水平也未显著升高。由于IL-4水平极低,仅在研究开始时进行了检测。与Der p组和安慰剂组相比,接受草花粉提取物治疗12个月后的患者NK细胞活性降低。在研究期间,患者未出现因IT导致的严重局部或全身副作用迹象。虽然在IT治疗的第一年结束时,已证明标准化提取物特异性IT在过敏性鼻炎和哮喘患者中具有显著的临床疗效,但未观察到免疫参数的显著变化。然而,我们得出结论,在患者随访过程中必须考虑IT治疗期间NK细胞细胞毒性活性的降低。